Business Standard

Sun Pharma rallies on FDA nod for cancer drug

USFDA have granted its subsidiary an approval for its ANDA for generic version of Doxil, Doxorubicin HCI liposome injection.

Related News

Sun Pharmaceutical Industries has rallied 4.4% to Rs 749 in morning trades after the company said US health regulators have approved a generic version of the drug Doxil.

“The U.S. Food and Drug Administration (USFDA) have granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) for generic version of Doxil, Doxorubicin HCI liposome injection,” said in a statement.

It will be available in 20 milligram and 50 milligram vials, it added.

Doxorubicin HCI liposome injection is used to treat patients with ovarian cancer that has progressed or recurred after platinum-based chemotherapy.

The stock opened at Rs 735 and touched high of Rs 752 on the NSE. A combined around 960,000 shares have changed hands on the counter in early morning deals on both the exchanges.

 

Read more on:   
|
|

Read More

UCO Bank slips on declining net

Shares of UCO Bank has slumped after the bank posted a sharp drop in net profit for the third quarter ended December 31, 2012.

Quick Links

 

Market News

Foreign investors submit bids worth Rs 3,640 cr for govt bonds

Auction was held for overseas investors at BSE's ebidxchange

Why OMCs are the best play in markets right now

Lower crude prices, higher margins and falling subsidies make OMC an attractive bet

Nifty ends above 7,900 for the first time after record high

The Nifty and Bank Nifty ended at record closing highs of 7,913 and 15,819, respectively

Sensex hovers around 26,400; IT and banks gain

At 14.45 PM, the BSE Sensex gained 58 points at 26, 422 while the CNX Nifty was up 21 points at 7,921

Hotel Leela Venture climbs 6% on news clarification

Hotel Leela Venture has surged 6% to Rs 25 on BSE after the company issued a clarification on the media news item.

Back to Top